Fenofibrate and the PPARα-YAP Axis: Liver Enlargement in Aging Mice

Study Background and Research Question

The liver, as a central organ for metabolism and detoxification, displays remarkable adaptability throughout life. Yet, aging is accompanied by physiological changes that can influence regenerative capacity and metabolic regulation. Nuclear receptors, particularly peroxisome proliferator-activated receptor alpha (PPARα), orchestrate key metabolic pathways, including lipid metabolism and hepatic growth responses. Fenofibrate, a widely studied PPARα agonist, has been shown to induce liver enlargement (hepatomegaly) in adult rodents, partially via interacting with the yes-associated protein (YAP) signaling pathway—an effector of the Hippo pathway linked to organ size regulation. However, whether Fenofibrate’s actions on liver growth and YAP pathway activation are preserved in aged livers remained an unresolved question. The current reference study directly addresses this gap, evaluating Fenofibrate-induced hepatomegaly and PPARα-YAP pathway activation in both adult and aging mouse models.

Key Innovation from the Reference Study

The principal innovation of this work lies in its systematic comparison of Fenofibrate’s effects on liver growth and signaling in adult versus aging mice, leveraging three distinct aging models (D-galactose-induced, naturally aged, and SAMP8 senescence-accelerated mice). The study rigorously demonstrates that Fenofibrate-induced liver enlargement, hepatocyte hypertrophy, and proliferation are equivalent in both age groups. Importantly, the activation of the PPARα-YAP signaling pathway by Fenofibrate is shown to be independent of aging, providing new mechanistic clarity for the use of PPARα agonists in gerontological metabolic research.

Methods and Experimental Design Insights

• Animal Models: The study deployed three aging models: D-galactose-induced aging, natural aging, and SAMP8 mice, alongside adult controls, to rigorously dissect age-dependence.
• Fenofibrate Administration: Mice received Fenofibrate, with dosing and treatment duration consistent with established protocols for inducing hepatic PPARα activation (see also Fenofibrate as a PPARα Agonist: Experimental Workflows & Innovation).
• Histological and Molecular Analyses: Liver weight, hepatocyte size (central vein and portal vein regions), and proliferation indices were quantified. Expression of PPARα downstream targets and YAP pathway effectors was measured by immunoblotting and immunohistochemistry.
• Comparative Approach: Direct side-by-side analysis allowed for robust determination of age effects on Fenofibrate-driven processes.

Protocol Parameters

• Fenofibrate dosing: Refer to prevailing mouse protocols for PPARα activation, typically 0.1–0.2% Fenofibrate in diet for 1–2 weeks, as supported by the reference study.
• Aging models: Employ D-galactose (100–150 mg/kg, i.p.) for induced aging, or use naturally aged (≥18 months) and SAMP8 mice for gerontological comparisons.
• Tissue sampling: Collect livers promptly after endpoint for histology and protein analysis to preserve YAP/PPARα pathway integrity.
• Solubility considerations: Fenofibrate is best dissolved in DMSO or ethanol and may require warming (37°C) or ultrasonic agitation for complete solubilization; see product information for further handling details.

Core Findings and Why They Matter

The study found that Fenofibrate-induced increases in liver weight, hepatocyte size (especially in the central vein region), and hepatocyte proliferation (notably in the portal vein area) were quantitatively similar between adult and aging mice. Molecular analyses confirmed that upregulation of canonical PPARα downstream proteins and proliferation-related YAP targets was equivalent across age groups. Notably, YAP nuclear translocation—a hallmark of pathway activation—was robustly induced in both adult and aged livers.

These findings indicate that the hepatic response to PPARα agonist stimulation is preserved with age, despite known age-related reductions in liver regeneration capacity after injury. This suggests a specific resilience of the PPARα-YAP axis to aging, which has implications for both basic liver biology and translational research targeting metabolic or degenerative liver diseases in the elderly. The results are especially relevant for researchers investigating age-independent drivers of organ plasticity and metabolic adaptation.

Comparison with Existing Internal Articles

Several internal resources offer complementary context on Fenofibrate’s roles in liver and cancer biology research. For example, Fenofibrate Activates PPARα-YAP Pathway Causing Liver Enlargement in Aging Mice summarizes similar findings, emphasizing that the hepatic growth response to Fenofibrate is not diminished by age. Meanwhile, Fenofibrate as a PPARα Agonist: Advanced Insights for Liver and Cancer Research extends the discussion to Fenofibrate’s cytotoxic effects in cancer cell models, highlighting the broader utility of PPARα agonists in experimental oncology. These resources collectively reinforce the robustness and transferability of the current study’s findings within the context of lipid metabolism research, cancer biology research, and age-related organ physiology.

Limitations and Transferability

While the study’s use of multiple aging models strengthens its conclusions, direct translation to human hepatic physiology remains to be validated, given species differences in liver size regulation and PPARα function. Additionally, the investigation focused exclusively on short-term Fenofibrate exposure and did not address potential cumulative or adverse effects with chronic administration. The results are most directly applicable to experimental setups modeling metabolic adaptation, aging, or PPARα-YAP pathway activation in the murine system. Researchers should also consider that while Fenofibrate’s activation of the PPARα-YAP axis is robust in both adult and aged mice, other nuclear receptor pathways may exhibit distinct age dependencies not addressed here.

Research Support Resources

To replicate or extend these findings, researchers can utilize Fenofibrate (SKU B1943), a well-characterized PPARα agonist suitable for investigations in lipid metabolism, cancer biology, and hepatic signaling pathways. Practical information regarding Fenofibrate’s solubility, storage, and handling can be found in the APExBIO product dossier. For detailed protocols and troubleshooting strategies, refer to the workflow articles cited above. This resource enables rigorous exploration of age-independent PPARα-YAP pathway activation and its implications for liver physiology.